Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05233098 · ClinicalTrials.gov registry record
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 6
- Enrollment target
NCT05233098: Completed study, sponsored by Boston Scientific Corporation.
NCT05233098 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05233098 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
Primary Outcome
To provide imaging data calculating radiation-delivered dose of Tc-99m MAA to the whole body.
Interventions
- DEVICE Technetium-99m macroaggregated albumin (Tc-99m MAA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2023-06-14 |
What the finished NCT05233098 record still lists
NCT05233098 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Technetium-99m macroaggregated albumin (Tc-99m MAA) is the first listed.
NCT05233098 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05233098 about?
NCT05233098 is a clinical study titled "TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.". The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
What is the current status of trial NCT05233098?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2022-04-04. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT05233098?
The interventions under investigation include: Technetium-99m macroaggregated albumin (Tc-99m MAA) (DEVICE).
Who is sponsoring clinical trial NCT05233098?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI